| |
|
|
|
Loews Philadelphia Hotel, Philadelphia, PA, USA
April 30 - May 2, 2014
April 30-May 1 - Executive Summit: Companion Diagnostics
- Translational Biomarkers in Drug Development
- Clinical Biomarker Assay Development
May 1-2 - Biomarkers for Patient Selection
- Mutation Analysis for Clinical Biomarkers and Diagnostics
Dinner Courses - Exosomes and Microvesicles as Cancer Biomarkers (April 29)
- Fit-for-Purpose Biomarker Assay Development and Validation (April 30)
- Non-Coding RNAs as Biomarkers and Diagnostics(April 30)
- Next-Generation Sequencing as a Clinical Test (May 1)
- Laboratory-Developed Tests (May 1)
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute |
|
|
Invited Speakers:
|
|
- John L. Allinson, FIBMS, Vice President, Biomarker Laboratory Services, ICON Development Solutions
- Jiri Aubrecht, Pharm.D., Ph.D., Senior Director and Safety Biomarker Group Lead, Drug Safety Research & Development, Pfizer
- Michael Berger, Ph.D., Assistant Professor, Pathology, Memorial Sloan-Kettering Cancer Center
- Mark S. Boguski, M.D., Ph.D., Associate Professor, Pathology, Center for Biomedical Informatics, Harvard Medical School
- Darrell R. Borger, Ph.D., Co-Director, Translational Research Laboratory; Director, Biomarker Laboratory, Massachusetts General Hospital and Harvard Medical School
- Michael Burczynski, Ph.D., Executive Director, Biomarker Technologies, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb
- Tracy Bush, Ph.D., Director, Companion Diagnostics Regulatory Affairs, Roche Diagnostics
- Derek Chiang, Ph.D., Research Investigator, Novartis Institutes for Biomedical Research
- Charles J. Cox, Ph.D., Head, Genetics Experiment Design and Delivery, GlaxoSmithKline
- Seth Crosby, M.D., Director, Partnerships & Alliances, Washington University School of Medicine
- Mark E. Curran, Ph.D., Vice President, Immunology, Systems Pharmacology & Biomarkers, Janssen Research & Development
- Viswanath Devanarayan, Ph.D., Global Head, Exploratory Statistics, AbbVie, Inc.
- Michael J. Donovan, M.D., Ph.D., Director, Experimental Pathology, Mt. Sinai School of Medicine
- Nicholas C. Dracopoli, Ph.D., Vice President, Janssen R&D, Johnson & Johnson
- Daniel Edelman, Ph.D., Core Manager, Clinical Molecular Profiling Core, National Cancer Institute, NIH
- Andrea Ferreira-Gonzalez, Ph.D., Professor and Chair, Division of Molecular Diagnostics; Director, Molecular Diagnostics Laboratory, Department of Pathology, Virginia Commonwealth University
- Helen Fernandes, Ph.D., Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College
- Andrew Fish, Executive Director, AdvaMedDx
- Felix W. Frueh, Ph.D., Executive Partner, Opus Three, LLC
- Iris Grossman, Ph.D., Global Head, Personalized Medicine and Pharmacogenomics, Teva Pharmaceutical
- Steven Gutman, M.D., Strategic Advisor, Myraqa
- Michael Hale, Ph.D., Executive Director, Medical Sciences Biostatistics, Amgen
- Sam Hanash, M.D., Ph.D., Director, McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center
- Xiaolan Hu, Ph.D., Head, Clinical Genetics, Bristol Myers Squibb
- Peter M. Kazon, General Counsel, American Clinical Laboratory Association
- Iya Khalil, Ph.D., Executive Vice President and Co-Founder, GNS Healthcare
- Marc Ladanyi, M.D., William Ruane Chair in Molecular Oncology; Member, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Eric Lai, Ph.D., Senior Vice President and Head, Pharmacogenomics, Takeda Pharmaceuticals International
- Towia Libermann, Ph.D., Associate Professor, Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School; Director, BIDMC Genomics, Proteomics, Bioinformatics, and Systems Biology Center and DF/HCC Cancer Proteomics Core
- Walter Lukiw, Ph.D., Professor, Neuroscience, Louisiana State University
- Rajyalakshmi Luthra, Ph.D., Professor, Hematopathology; Director, Molecular Genetic Pathology Fellowship Program; Director, Molecular Diagnostic Laboratory, MD Anderson Cancer Center
- Ron Mazumder, Ph.D., MBA, Global Head, R&D and Operations, Janssen Diagnostics, Janssen Pharmaceutical Companies of Johnson & Johnson
- Donna L. Mendrick, Ph.D., Director, Systems Biology, NCTR, FDA
- Christopher-Paul Milne, DVM, MPH, J.D., Assistant Research Professor, Director, Research, Center for the Study of Drug Development, Tufts University Medical School
- Nirmala Nanguneri, Ph.D., Director and Head, Biomarker Analysis and Informatics, Novartis Institutes for Biomedical Research
- Jonathan Pan, Director, Oncology Companion Diagnostic & Disease Strategy, GlaxoSmithKline
- Saumya Pant, Ph.D., Research Fellow, Merck
- Abhijit Patel, M.D., Ph.D., Assistant Professor, Therapeutic Radiology, Yale University School of Medicine
- Rajesh Patel, Ph.D., Scientific Manager, Oncology Biomarker Development, Genentech
- Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen
- Suso Platero, Ph.D., Director, Oncology Biomarkers, Janssen Pharmaceuticals
- Victor Prieto, M.D., Ph.D., Professor, Pathology and Dermatology, MD Anderson Cancer Center
- Mitch Raponi, Ph.D., Senior Director, Molecular Diagnostics, Clovis Oncology
- Tarek Sahmoud, M.D., Ph.D., Corporate Vice President, Clinical Research and Development, Celgene Corporation
- Andrew Schade, M.D., Ph.D., Senior Director, Diagnostics and Experimental Pathology, Tailored Therapeutics, Eli Lilly and Company
- Cecilia Schott, Pharm.D., MBA, Head, Personalized Healthcare, Corporate Business Development, AstraZeneca
- Andreas Schuppert, Ph.D., Vice President, Technology Development, Bayer Technology Services GmbH; Professor, AICES, RWTH Aachen University
- Corinne Solier, Ph.D., Leader, ClinicalProtein Biomarkers, F. Hoffmann-La Roche
- Kári Stefánsson, M.D., CEO, deCODE Genetics
- Douglas D. Taylor, Ph.D., CSO, Exosome Sciences
- Liling Warren, Ph.D., Senior Scientific Investigator, GlaxoSmithKline
- Bo Wei, MS, Associate Principal Scientist, Molecular Biomarker and Diagnostics, Merck
- Russell S. Weiner, Ph.D., Executive Director and Head, Molecular Biomarkers and Diagnostics, Merck
- Jens R. Wendland, M.D., Director and Head, Neuroscience Genetics, Pfizer Worldwide R&D
- P. Mickey Williams, Ph.D., Director, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research
- Hang Hubert Yin, Ph.D., Associate Professor, Chemistry and Biochemistry, University of Colorado Boulder
- Jenny Zhang, Ph.D., Senior Scientist, Pfizer
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|